Surgical Management


Ambulatory Intra Aortic Balloon Pump in Advanced Heart Failure

Heart failure is a progressive and fatal disease that affects more than 23 million people worldwide, and will affect more than 8 million people in the USA by 2030.1,2 Despite major advancements in medical and device treatments for heart failure in recent decades, the incidence of heart failure continues to rise. This epidemic has a major impact on patient quality of life, while imposing heavy costs on the healthcare system.

Chagas Heart Failure in Patients from Latin America

More than a century after its discovery, Chagas disease still is a major health problem in Latin America, with 5.7 million people in 21 countries being affected by it.1 Moreover, about 70 million people are at risk of acquiring the illness.1 Cases of Chagas disease are now found globally; there are more than 400,000 immigrants with this disease living in Europe (mainly in Spain, Italy and France) and the United States.2 The consequence of this is that the annual global (direct plus indirect) cost of the disease is in the region of US $7.2 b

Shock Management for Cardio-surgical ICU Patients – The Golden Hours

Shock in cardio-surgical intensive care unit (ICU) patients is a serious condition with a high morbidity and mortality.1,2 Prompt identification of the underlying conditions and correct management of the life- threatening physiological deteriorations are crucial to save the patient’s life. In daily practice, however, focusing on the main goal – to provide adequate oxygen delivery thereby preventing further organ damage – is often difficult due to multiple influences, distractions, and pending results. Hence, the setting up of priorities is necessary.

Managing Heart Failure Patients with Multivessel Disease – Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention

The most common cause of heart failure with reduced ejection fraction (HFrEF) in the industrialised world is coronary heart disease.1 Patients with an ischaemic aetiology of left ventricular systolic dysfunction have significantly higher mortality rates than those with non-ischaemic aetiologies.2 This more aggressive course represents the convergence of ischaemic myocardial fibrosis and endothelial dysfunction, which are superimposed on the progressive nature of the left ventricular dysfunc